Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Recruiting
NCT07033494Phase 2Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Early Alzheimer's Disease
United States, Argentina, Australia, Belgium, Canada +6 more
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Recruiting
NCT07419295Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer
United States, Argentina, Australia, Belgium, Brazil +11 more
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Active Not Recruiting
NCT04736706Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States, Australia, Brazil, Canada, Chile +30 more
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Recruiting
NCT06966700Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +34 more
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Recruiting
NCT06824467Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)Completed
NCT04924101Phase 2Updated Aug 13, 2026
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Cancer
United States, Austria, Canada, Hungary, Israel +6 more
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell CarcinomaRecruiting
NCT05733715EARLY_Phase 1Updated Aug 13, 2026
Sponsor: Abramson Cancer Center at Penn Medicine
Renal Cell Carcinoma
United States
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Recruiting
NCT06136650Phase 3Updated Aug 13, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer (mCRPC) · Prostatic Neoplasms
United States, Australia, Brazil, Canada, Chile +34 more
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Active Not Recruiting
NCT04170153Phase 1Updated Aug 13, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Metastatic or Locally Advanced Unresectable Solid Tumors
United States, China, Japan, Spain, United Kingdom
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)Completed
NCT04305041Phase 1, Phase 2Updated Aug 13, 2026
Sponsor: Merck Sharp & Dohme LLC
Melanoma
United States, Australia, France, Israel, Italy +2 more
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PNActive Not Recruiting
NCT05309668Phase 1, Phase 2Updated Aug 13, 2026
Sponsor: AstraZeneca
Neurofibromatosis Type 1
United States, Germany, Italy, Japan, Netherlands +2 more
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active Not Recruiting
NCT06079879Phase 3Updated Aug 13, 2026
Sponsor: Merck Sharp & Dohme LLC
Essential Thrombocythemia
United States, Argentina, Australia, Belgium, Canada +19 more
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)Not Yet Recruiting
NCT07700758Phase 2Updated Aug 13, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsTerminated
NCT05572684Phase 1, Phase 2Updated Aug 13, 2026
Sponsor: NextCure, Inc.
Advanced or Metastatic Solid Tumors · Microsatellite Instability Low · Microsatellite Instability High · Microsatellite Stable
United States
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical CancerRecruiting
NCT06543576Phase 1, Phase 2Updated Aug 12, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma · Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8
United States
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid TumorsRecruiting
NCT06234397Phase 1Updated Aug 12, 2026
Sponsor: Hanmi Pharmaceutical Company Limited
Advanced or Metastatic Solid Tumors
United States, South Korea
Anti-GD2 ADC M3554 in Advanced Solid TumorsRecruiting
NCT06641908Phase 1Updated Aug 12, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumor
United States, Belgium, France, Japan, Switzerland +1 more
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Recruiting
NCT06463587Phase 3Updated Aug 12, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Generalized Myasthenia Gravis
United States, Argentina, Australia, Belgium, Bulgaria +20 more
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruiting
NCT07194980Phase 2Updated Aug 12, 2026
Sponsor: Fred Hutchinson Cancer Center
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
United States
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal MelanomaTerminated
NCT05308901Phase 2Updated Aug 12, 2026
Sponsor: Providence Health & Services
Melanoma, Uveal
United States
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial CarcinomaActive Not Recruiting
NCT05929235Phase 1Updated Aug 12, 2026
Sponsor: Flare Therapeutics Inc.
Advanced Urothelial Carcinoma · Oral Drug Administration · Open Label
United States
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)Recruiting
NCT04665037Phase 2Updated Aug 12, 2026
Sponsor: Merck Sharp & Dohme LLC
Invasive Fungal Infection
United States, Belgium, Greece, Israel, Mexico +5 more
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer SurvivorsTerminated
NCT06162663Phase 4Updated Aug 12, 2026
Sponsor: Medical University of South Carolina
Breast Cancer · Insomnia
United States
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsActive Not Recruiting
NCT06806046Phase 1Updated Aug 11, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Solid Tumors · Colorectal Cancer
China
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment StudyCompleted
NCT06412848N/AUpdated Aug 11, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Urothelial Carcinoma
Japan

Previous page Next page